vs
Adaptive Biotechnologies Corp（ADPT）とHALOZYME THERAPEUTICS, INC.（HALO）の財務データ比較。上の社名をクリックして会社を切り替えられます
HALOZYME THERAPEUTICS, INC.の直近四半期売上が大きい（$451.8M vs $71.7M、Adaptive Biotechnologies Corpの約6.3倍）。Adaptive Biotechnologies Corpの純利益率が高く（-18.9% vs -31.3%、差は12.4%）。HALOZYME THERAPEUTICS, INC.の前年同期比売上増加率が高い（51.6% vs 51.0%）。HALOZYME THERAPEUTICS, INC.の直近四半期フリーキャッシュフローが多い（$217.6M vs $1.4M）。過去8四半期でHALOZYME THERAPEUTICS, INC.の売上複合成長率が高い（51.9% vs 30.8%）
ExpreS2ionバイオテクノロジーズはデンマークのホルスホルムに本拠を置くバイオテクノロジー企業で、新規ワクチンと免疫療法製品の開発を専門としており、スウェーデンのナスダック・ファーストノース成長市場に上場しています。
Halozyme Therapeutics社は米国のバイオテクノロジー企業で、腫瘍微小環境を標的としたがん治療法の開発に特化しています。より安全性が高く有効な治療選択肢をがん患者に提供することを目標に、研究開発に取り組んでいます。
ADPT vs HALO — 直接比較
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $71.7M | $451.8M |
| 純利益 | $-13.6M | $-141.6M |
| 粗利率 | 74.6% | 82.6% |
| 営業利益率 | -17.8% | -20.6% |
| 純利益率 | -18.9% | -31.3% |
| 売上前年比 | 51.0% | 51.6% |
| 純利益前年比 | 59.7% | -203.3% |
| EPS（希薄化後） | $-0.08 | $-1.13 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $71.7M | $451.8M | ||
| Q3 25 | $94.0M | $354.3M | ||
| Q2 25 | $58.9M | $325.7M | ||
| Q1 25 | $52.4M | $264.9M | ||
| Q4 24 | $47.5M | $298.0M | ||
| Q3 24 | $46.4M | $290.1M | ||
| Q2 24 | $43.2M | $231.4M | ||
| Q1 24 | $41.9M | $195.9M |
| Q4 25 | $-13.6M | $-141.6M | ||
| Q3 25 | $9.5M | $175.2M | ||
| Q2 25 | $-25.6M | $165.2M | ||
| Q1 25 | $-29.9M | $118.1M | ||
| Q4 24 | $-33.7M | $137.0M | ||
| Q3 24 | $-32.1M | $137.0M | ||
| Q2 24 | $-46.2M | $93.2M | ||
| Q1 24 | $-47.5M | $76.8M |
| Q4 25 | 74.6% | 82.6% | ||
| Q3 25 | 80.7% | 84.4% | ||
| Q2 25 | 69.4% | 85.8% | ||
| Q1 25 | 67.6% | 81.7% | ||
| Q4 24 | 62.0% | 85.9% | ||
| Q3 24 | 64.1% | 83.0% | ||
| Q2 24 | 55.3% | 82.9% | ||
| Q1 24 | 56.9% | 85.5% |
| Q4 25 | -17.8% | -20.6% | ||
| Q3 25 | 10.9% | 61.5% | ||
| Q2 25 | -42.5% | 62.2% | ||
| Q1 25 | -56.4% | 53.4% | ||
| Q4 24 | -71.3% | 58.9% | ||
| Q3 24 | -70.3% | 56.3% | ||
| Q2 24 | -109.6% | 50.7% | ||
| Q1 24 | -116.5% | 48.8% |
| Q4 25 | -18.9% | -31.3% | ||
| Q3 25 | 10.2% | 49.5% | ||
| Q2 25 | -43.5% | 50.7% | ||
| Q1 25 | -56.9% | 44.6% | ||
| Q4 24 | -71.0% | 46.0% | ||
| Q3 24 | -69.1% | 47.2% | ||
| Q2 24 | -107.0% | 40.3% | ||
| Q1 24 | -113.5% | 39.2% |
| Q4 25 | $-0.08 | $-1.13 | ||
| Q3 25 | $0.06 | $1.43 | ||
| Q2 25 | $-0.17 | $1.33 | ||
| Q1 25 | $-0.20 | $0.93 | ||
| Q4 24 | $-0.22 | $1.06 | ||
| Q3 24 | $-0.22 | $1.05 | ||
| Q2 24 | $-0.31 | $0.72 | ||
| Q1 24 | $-0.33 | $0.60 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $70.5M | $133.8M |
| 総負債低いほど良い | — | $2.1B |
| 株主資本純資産 | $218.8M | $48.8M |
| 総資産 | $512.7M | $2.5B |
| 負債/資本比率低いほどレバレッジが低い | — | 43.89× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $70.5M | $133.8M | ||
| Q3 25 | $55.0M | $419.7M | ||
| Q2 25 | $43.2M | $61.9M | ||
| Q1 25 | $50.6M | $176.3M | ||
| Q4 24 | $47.9M | $115.8M | ||
| Q3 24 | $38.1M | $154.3M | ||
| Q2 24 | $59.8M | $187.9M | ||
| Q1 24 | $71.2M | $164.6M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
| Q4 25 | $218.8M | $48.8M | ||
| Q3 25 | $204.4M | $503.9M | ||
| Q2 25 | $179.7M | $332.7M | ||
| Q1 25 | $190.4M | $482.3M | ||
| Q4 24 | $202.7M | $363.8M | ||
| Q3 24 | $223.8M | $452.7M | ||
| Q2 24 | $241.6M | $289.4M | ||
| Q1 24 | $274.9M | $177.8M |
| Q4 25 | $512.7M | $2.5B | ||
| Q3 25 | $490.6M | $2.2B | ||
| Q2 25 | $496.6M | $2.1B | ||
| Q1 25 | $510.9M | $2.2B | ||
| Q4 24 | $539.4M | $2.1B | ||
| Q3 24 | $558.5M | $2.1B | ||
| Q2 24 | $584.9M | $2.0B | ||
| Q1 24 | $620.3M | $1.8B |
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $2.1M | $219.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $1.4M | $217.6M |
| FCFマージンFCF / 売上 | 2.0% | 48.2% |
| 設備投資強度設備投資 / 売上 | 0.9% | 0.3% |
| キャッシュ転換率営業CF / 純利益 | — | — |
| 直近12ヶ月FCF直近4四半期 | $-48.9M | $644.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $2.1M | $219.0M | ||
| Q3 25 | $-7.1M | $178.6M | ||
| Q2 25 | $-12.4M | $99.7M | ||
| Q1 25 | $-28.5M | $154.2M | ||
| Q4 24 | $-12.5M | $178.5M | ||
| Q3 24 | $-27.1M | $115.4M | ||
| Q2 24 | $-17.3M | $55.8M | ||
| Q1 24 | $-38.4M | $129.4M |
| Q4 25 | $1.4M | $217.6M | ||
| Q3 25 | $-7.5M | $175.6M | ||
| Q2 25 | $-13.1M | $98.1M | ||
| Q1 25 | $-29.7M | $153.3M | ||
| Q4 24 | $-12.6M | $175.4M | ||
| Q3 24 | $-27.4M | $113.9M | ||
| Q2 24 | $-19.0M | $53.2M | ||
| Q1 24 | $-39.9M | $125.9M |
| Q4 25 | 2.0% | 48.2% | ||
| Q3 25 | -8.0% | 49.6% | ||
| Q2 25 | -22.2% | 30.1% | ||
| Q1 25 | -56.7% | 57.9% | ||
| Q4 24 | -26.5% | 58.9% | ||
| Q3 24 | -59.0% | 39.3% | ||
| Q2 24 | -44.1% | 23.0% | ||
| Q1 24 | -95.2% | 64.3% |
| Q4 25 | 0.9% | 0.3% | ||
| Q3 25 | 0.4% | 0.9% | ||
| Q2 25 | 1.1% | 0.5% | ||
| Q1 25 | 2.4% | 0.4% | ||
| Q4 24 | 0.2% | 1.0% | ||
| Q3 24 | 0.7% | 0.5% | ||
| Q2 24 | 4.0% | 1.1% | ||
| Q1 24 | 3.6% | 1.8% |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 1.68× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
